Cargando…
Targeting self-renewal pathways in cancer stem cells: clinical implications for cancer therapy
Extensive cancer research in the past few decades has identified the existence of a rare subpopulation of stem cells in the grove of cancer cells. These cells are known as the cancer stem cells marked by the presence of surface biomarkers, multi-drug resistance pumps and deregulated self-renewal pat...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4670961/ https://www.ncbi.nlm.nih.gov/pubmed/26619402 http://dx.doi.org/10.1038/oncsis.2015.35 |
_version_ | 1782404335017132032 |
---|---|
author | Borah, A Raveendran, S Rochani, A Maekawa, T Kumar, D S |
author_facet | Borah, A Raveendran, S Rochani, A Maekawa, T Kumar, D S |
author_sort | Borah, A |
collection | PubMed |
description | Extensive cancer research in the past few decades has identified the existence of a rare subpopulation of stem cells in the grove of cancer cells. These cells are known as the cancer stem cells marked by the presence of surface biomarkers, multi-drug resistance pumps and deregulated self-renewal pathways (SRPs). They have a crucial role in provoking cancer cells leading to tumorigenesis and its progressive metastasis. Cancer stem cells (CSCs) are much alike to normal stem cells in their self-renewal mechanisms. However, deregulations in the SRPs are seen in CSCs, making them resistant to conventional chemotherapeutic agents resulting in the tumor recurrence. Current treatment strategies in cancer fail to detect and differentiate the CSCs from their non-tumorigenic progenies owing to absence of specific biomarkers. Now, it has become imperative to understand complex functional biology of CSCs, especially the signaling pathways to design improved treatment strategies to target them. It is hopeful that the SRPs in CSCs offer a promising target to alter their survival strategies and impede their tumorigenic potential. However, there are many perils associated with the direct targeting method by conventional therapeutic agents such as off targets, poor bioavailability and poor cellular distribution. Recent evidences have shown an increased use of small molecule antagonists directly to target these SRPs may lead to severe side-effects. An alternative to solve these issues could be an appropriate nanoformulation. Nanoformulations of these molecules could provide an added advantage for the selective targeting of the pathways especially Hedgehog, Wnt, Notch and B-cell-specific moloney murine leukemia virus integration site 1 in the CSCs while sparing the normal stem cells. Hence, to achieve this goal a complete understanding of the molecular pathways corroborate with the use of holistic nanosystem (nanomaterial inhibition molecule) could possibly be an encouraging direction for future cancer therapy. |
format | Online Article Text |
id | pubmed-4670961 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-46709612015-12-14 Targeting self-renewal pathways in cancer stem cells: clinical implications for cancer therapy Borah, A Raveendran, S Rochani, A Maekawa, T Kumar, D S Oncogenesis Review Extensive cancer research in the past few decades has identified the existence of a rare subpopulation of stem cells in the grove of cancer cells. These cells are known as the cancer stem cells marked by the presence of surface biomarkers, multi-drug resistance pumps and deregulated self-renewal pathways (SRPs). They have a crucial role in provoking cancer cells leading to tumorigenesis and its progressive metastasis. Cancer stem cells (CSCs) are much alike to normal stem cells in their self-renewal mechanisms. However, deregulations in the SRPs are seen in CSCs, making them resistant to conventional chemotherapeutic agents resulting in the tumor recurrence. Current treatment strategies in cancer fail to detect and differentiate the CSCs from their non-tumorigenic progenies owing to absence of specific biomarkers. Now, it has become imperative to understand complex functional biology of CSCs, especially the signaling pathways to design improved treatment strategies to target them. It is hopeful that the SRPs in CSCs offer a promising target to alter their survival strategies and impede their tumorigenic potential. However, there are many perils associated with the direct targeting method by conventional therapeutic agents such as off targets, poor bioavailability and poor cellular distribution. Recent evidences have shown an increased use of small molecule antagonists directly to target these SRPs may lead to severe side-effects. An alternative to solve these issues could be an appropriate nanoformulation. Nanoformulations of these molecules could provide an added advantage for the selective targeting of the pathways especially Hedgehog, Wnt, Notch and B-cell-specific moloney murine leukemia virus integration site 1 in the CSCs while sparing the normal stem cells. Hence, to achieve this goal a complete understanding of the molecular pathways corroborate with the use of holistic nanosystem (nanomaterial inhibition molecule) could possibly be an encouraging direction for future cancer therapy. Nature Publishing Group 2015-11 2015-11-30 /pmc/articles/PMC4670961/ /pubmed/26619402 http://dx.doi.org/10.1038/oncsis.2015.35 Text en Copyright © 2015 Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ Oncogenesis is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Review Borah, A Raveendran, S Rochani, A Maekawa, T Kumar, D S Targeting self-renewal pathways in cancer stem cells: clinical implications for cancer therapy |
title | Targeting self-renewal pathways in cancer stem cells: clinical implications for cancer therapy |
title_full | Targeting self-renewal pathways in cancer stem cells: clinical implications for cancer therapy |
title_fullStr | Targeting self-renewal pathways in cancer stem cells: clinical implications for cancer therapy |
title_full_unstemmed | Targeting self-renewal pathways in cancer stem cells: clinical implications for cancer therapy |
title_short | Targeting self-renewal pathways in cancer stem cells: clinical implications for cancer therapy |
title_sort | targeting self-renewal pathways in cancer stem cells: clinical implications for cancer therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4670961/ https://www.ncbi.nlm.nih.gov/pubmed/26619402 http://dx.doi.org/10.1038/oncsis.2015.35 |
work_keys_str_mv | AT boraha targetingselfrenewalpathwaysincancerstemcellsclinicalimplicationsforcancertherapy AT raveendrans targetingselfrenewalpathwaysincancerstemcellsclinicalimplicationsforcancertherapy AT rochania targetingselfrenewalpathwaysincancerstemcellsclinicalimplicationsforcancertherapy AT maekawat targetingselfrenewalpathwaysincancerstemcellsclinicalimplicationsforcancertherapy AT kumards targetingselfrenewalpathwaysincancerstemcellsclinicalimplicationsforcancertherapy |